表皮生长因子受体 (EGFR)在许多肿瘤细胞中扩增、缺失和 /或突变。迄今为止 ,已发现三种不同的EGFR胞外区缺失突变体 ,即EGFRⅥ ,EGFRⅦ及EGFRⅧ型。EGFR及其突变体借助于信号传导使细胞生长失控和恶性化。因此 ,以其为靶的肿瘤治疗引起人们关注 ,并取得了一些令人瞩目的进展。如针对EGFR的特异性抗体、通过反义核苷酸阻断EGFRmRNA翻译、用酪氨酸激酶抑制子阻断EGFR酪氨酸激酶的活性 ,有效地阻断了癌变的演进。 Epidermal growth factor receptor (EGFR) is amplified, deleted and/or mutated in many tumor cells. To date, three different deletion mutants of the extracellular domain of EGFR, EGFRVI, EGFRVII, and EGFRVIII, have been discovered. EGFR and its mutants uncontrolled and malignant cell growth through signal transduction. Therefore, the treatment of tumors targeting it has drawn attention and made some remarkable progress. For example, specific antibodies against EGFR, blocking of EGFR mRNA translation by antisense nucleotides, and blocking of EGFR tyrosine kinase activity with tyrosine kinase inhibitors effectively block the progression of canceration.